SANOFI-AVENTIS (EPA:SAN) Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer
Transparency directive : regulatory news
05/08/2021 12:00
SANOFI-AVENTIS's latest news
17/04/2024 07:00
12/04/2024 20:05
22/03/2024 07:30
15/03/2024 20:04
24/02/2024 15:51
23/02/2024 18:45
23/02/2024 07:00
22/02/2024 19:02
20/02/2024 23:40
15/02/2024 14:00
Other stories
24/04/2024 04:36
23/04/2024 23:26
24/04/2024 03:22
24/04/2024 03:30
24/04/2024 01:09
24/04/2024 03:51
24/04/2024 02:08
24/04/2024 06:45
23/04/2024 18:08
23/04/2024 17:57
23/04/2024 23:38
24/04/2024 03:01
23/04/2024 23:17
23/04/2024 23:15
24/04/2024 05:36
23/04/2024 13:53
23/04/2024 15:13
23/04/2024 17:48
23/04/2024 06:14
22/04/2024 23:45
23/04/2024 19:32
23/04/2024 18:19
24/04/2024 03:36
24/04/2024 07:42
24/04/2024 02:28
24/04/2024 04:38
24/04/2024 00:59
23/04/2024 21:52
23/04/2024 22:59
24/04/2024 02:00
23/04/2024 20:39
23/04/2024 19:00
24/04/2024 01:01
22/04/2024 18:16
24/04/2024 06:00
23/04/2024 20:17
24/04/2024 02:18
23/04/2024 08:55